SG11202102821QA - Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation - Google Patents

Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation

Info

Publication number
SG11202102821QA
SG11202102821QA SG11202102821QA SG11202102821QA SG11202102821QA SG 11202102821Q A SG11202102821Q A SG 11202102821QA SG 11202102821Q A SG11202102821Q A SG 11202102821QA SG 11202102821Q A SG11202102821Q A SG 11202102821QA SG 11202102821Q A SG11202102821Q A SG 11202102821QA
Authority
SG
Singapore
Prior art keywords
therapy
exposure
symptoms related
lethal radiation
pentandioic acid
Prior art date
Application number
SG11202102821QA
Other languages
English (en)
Inventor
Dirk Pleimes
Original Assignee
Myelo Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelo Therapeutics Gmbh filed Critical Myelo Therapeutics Gmbh
Publication of SG11202102821QA publication Critical patent/SG11202102821QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202102821QA 2018-09-25 2019-09-25 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation SG11202102821QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18196490 2018-09-25
EP19164201 2019-03-20
PCT/EP2019/075853 WO2020064832A1 (en) 2018-09-25 2019-09-25 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation

Publications (1)

Publication Number Publication Date
SG11202102821QA true SG11202102821QA (en) 2021-04-29

Family

ID=68109291

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102821QA SG11202102821QA (en) 2018-09-25 2019-09-25 Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation

Country Status (9)

Country Link
US (1) US20210275498A1 (de)
EP (1) EP3856175A1 (de)
JP (1) JP7531918B2 (de)
KR (1) KR20210083266A (de)
CN (1) CN112770743A (de)
CA (1) CA3113478A1 (de)
IL (1) IL281652A (de)
SG (1) SG11202102821QA (de)
WO (1) WO2020064832A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855445B2 (en) 2016-04-01 2018-01-02 Varian Medical Systems, Inc. Radiation therapy systems and methods for delivering doses to a target volume
US10549117B2 (en) 2017-07-21 2020-02-04 Varian Medical Systems, Inc Geometric aspects of radiation therapy planning and treatment
US11712579B2 (en) 2017-07-21 2023-08-01 Varian Medical Systems, Inc. Range compensators for radiation therapy
US10092774B1 (en) 2017-07-21 2018-10-09 Varian Medical Systems International, AG Dose aspects of radiation therapy planning and treatment
US11590364B2 (en) 2017-07-21 2023-02-28 Varian Medical Systems International Ag Material inserts for radiation therapy
US10843011B2 (en) 2017-07-21 2020-11-24 Varian Medical Systems, Inc. Particle beam gun control systems and methods
US10183179B1 (en) 2017-07-21 2019-01-22 Varian Medical Systems, Inc. Triggered treatment systems and methods
US11007381B2 (en) 2017-11-16 2021-05-18 Varian Medical Systems, Inc Increased beam output and dynamic field shaping for radiotherapy system
US10910188B2 (en) 2018-07-25 2021-02-02 Varian Medical Systems, Inc. Radiation anode target systems and methods
US10814144B2 (en) 2019-03-06 2020-10-27 Varian Medical Systems, Inc. Radiation treatment based on dose rate
US11116995B2 (en) 2019-03-06 2021-09-14 Varian Medical Systems, Inc. Radiation treatment planning based on dose rate
US11103727B2 (en) 2019-03-08 2021-08-31 Varian Medical Systems International Ag Model based PBS optimization for flash therapy treatment planning and oncology information system
US11090508B2 (en) 2019-03-08 2021-08-17 Varian Medical Systems Particle Therapy Gmbh & Co. Kg System and method for biological treatment planning and decision support
US10918886B2 (en) 2019-06-10 2021-02-16 Varian Medical Systems, Inc. Flash therapy treatment planning and oncology information system having dose rate prescription and dose rate mapping
US11291859B2 (en) 2019-10-03 2022-04-05 Varian Medical Systems, Inc. Radiation treatment planning for delivering high dose rates to spots in a target
US11865361B2 (en) 2020-04-03 2024-01-09 Varian Medical Systems, Inc. System and method for scanning pattern optimization for flash therapy treatment planning
US11541252B2 (en) 2020-06-23 2023-01-03 Varian Medical Systems, Inc. Defining dose rate for pencil beam scanning
US11957934B2 (en) 2020-07-01 2024-04-16 Siemens Healthineers International Ag Methods and systems using modeling of crystalline materials for spot placement for radiation therapy
US12064645B2 (en) 2020-07-02 2024-08-20 Siemens Healthineers International Ag Methods and systems used for planning radiation treatment
CN115088675A (zh) * 2022-07-07 2022-09-23 南昌大学 一种新型电离辐射导致睾丸损伤模型的构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток

Also Published As

Publication number Publication date
KR20210083266A (ko) 2021-07-06
EP3856175A1 (de) 2021-08-04
CN112770743A (zh) 2021-05-07
CA3113478A1 (en) 2020-04-02
JP7531918B2 (ja) 2024-08-13
US20210275498A1 (en) 2021-09-09
WO2020064832A1 (en) 2020-04-02
IL281652A (en) 2021-05-31
JP2022502506A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
IL281652A (en) IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID FOR USE IN THE TREATMENT OF SYMPTOMS RELATED TO EXPOSURE TO LETHAL RADIATION
HK1259149A1 (zh) 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途
IL285614A (en) Oral peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory bowel diseases
IL275321A (en) Treatment of diseases associated with the expression of DUX4
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
IL262472A (en) dpp3 suppressors for use in the treatment of diseases associated with necrosis
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
IL255818A (en) Pentosan polysulfate sodium for the treatment of sickle cell disease
BR112013019011A2 (pt) inibição de il17 e ifn-gama para o tratamento de inflamação autoimune
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
IL280163A (en) Mitochondrial augmentation therapy for primary mitochondrial diseases
IL268930A (en) Citrulline for the treatment of sickle cell crisis
GB201709917D0 (en) Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy
IL290756A (en) Treatment of azoles
EP3151735A4 (de) Hyperspektrale bildgebung zur vorhersage von hautschäden nach aussetzung gegenüber wärmeenergie oder ionisierender strahlung
FR3017624B1 (fr) Methode predictive pour caracteriser la radiosensibilite et la reaction tissulaire d'un patient envers un rayonnement ionisant therapeutique
IL243637B (en) PPAR-sparing compounds for the treatment of metabolic diseases
GB2562661B (en) Oil palm phenolics composition for the protection of human organs, cells and tissues against the injurious effects of exposure to ionizing radiation
PL3369435T3 (pl) Kompozycja do leczenia choroby zapalnej stawów
PL3364971T3 (pl) Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu
PL2997158T3 (pl) Sposób wyznaczania ryzyka powstania toksyczności wywołanej promieniowaniem po ekspozycji na promieniowanie
ZA201707777B (en) Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
EP3534932C0 (de) Behandlung von krankheiten im zusammenhang mit igfb3 und dessen rezeptor
MA46476A (fr) Compositions pharmaceutiques destinées au traitement des maladies liées au régulateur de la conductance transmembranaire de la mucoviscidose